7-octadecynoic acid

7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.

Cross Reference

There are no associated biomedical information in the current reference collection.

Current reference collection contains 19785 references associated with 7-octadecynoic acid in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.

Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.


Here are additional resources we collected from PubChem and MeSH for 7-octadecynoic acid

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid

MeSH term MeSH ID Detail
Atrial Remodeling D064752 1 associated lipids
Vascular Calcification D061205 1 associated lipids
Angina, Stable D060050 2 associated lipids
Bisphosphonate-Associated Osteonecrosis of the Jaw D059266 1 associated lipids
Osteoporotic Fractures D058866 1 associated lipids
Peripheral Arterial Disease D058729 7 associated lipids
Plaque, Atherosclerotic D058226 7 associated lipids
Peri-Implantitis D057873 1 associated lipids
Primary Myelofibrosis D055728 6 associated lipids
Chronic Periodontitis D055113 1 associated lipids
Osteophyte D054850 2 associated lipids
Hyperphosphatemia D054559 1 associated lipids
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative D054438 1 associated lipids
No-Reflow Phenomenon D054318 2 associated lipids
Acute Coronary Syndrome D054058 11 associated lipids
Hypercalciuria D053565 4 associated lipids
Renal Insufficiency, Chronic D051436 9 associated lipids
Fractures, Bone D050723 4 associated lipids
Arteriolosclerosis D050379 1 associated lipids
Atherosclerosis D050197 85 associated lipids
Dyslipidemias D050171 7 associated lipids
Hashimoto Disease D050031 1 associated lipids
Hyperparathyroidism, Primary D049950 1 associated lipids
Diabetes Complications D048909 4 associated lipids
Hypertension, Pregnancy-Induced D046110 2 associated lipids
Scleroderma, Limited D045745 1 associated lipids
Glucose Metabolism Disorders D044882 3 associated lipids
Malnutrition D044342 6 associated lipids
Irritable Bowel Syndrome D043183 8 associated lipids
Mastocytoma D034801 3 associated lipids
Hearing Loss D034381 3 associated lipids
Pulmonary Disease, Chronic Obstructive D029424 16 associated lipids
Spondylarthropathies D025242 1 associated lipids
Spondylarthritis D025241 1 associated lipids
Metabolic Syndrome D024821 44 associated lipids
Coronary Stenosis D023921 6 associated lipids
Carcinoma, Pancreatic Ductal D021441 6 associated lipids
Multiple Sclerosis, Relapsing-Remitting D020529 7 associated lipids
Multiple Sclerosis, Chronic Progressive D020528 3 associated lipids
Brain Infarction D020520 17 associated lipids
Osteoarthritis, Knee D020370 13 associated lipids
Lithiasis D020347 2 associated lipids
Ventricular Remodeling D020257 28 associated lipids
Tooth Ankylosis D020254 1 associated lipids
Venous Thrombosis D020246 11 associated lipids
Intracranial Hemorrhage, Traumatic D020198 1 associated lipids
Sleep Apnea, Obstructive D020181 9 associated lipids
Genetic Predisposition to Disease D020022 24 associated lipids
Hepatitis C, Chronic D019698 12 associated lipids
Hot Flashes D019584 5 associated lipids
Per page 10 20 50 100 | Total 298

All references with 7-octadecynoic acid

Download all related citations
Per page 10 20 50 100 | Total 4091
Authors Title Published Journal PubMed Link
Shioi A et al. Induction of bone-type alkaline phosphatase in human vascular smooth muscle cells: roles of tumor necrosis factor-alpha and oncostatin M derived from macrophages. 2002 Circ. Res. pmid:12114316
Lipton A et al. Serum osteoprotegerin levels in healthy controls and cancer patients. 2002 Clin. Cancer Res. pmid:12114435
Fujita T et al. SPARC stimulates the synthesis of OPG/OCIF, MMP-2 and DNA in human periodontal ligament cells. 2002 J. Oral Pathol. Med. pmid:12201246
Juji T et al. A novel therapeutic vaccine approach, targeting RANKL, prevents bone destruction in bone-related disorders. 2002 J. Bone Miner. Metab. pmid:12203031
Grisar J et al. Ankylosing spondylitis, psoriatic arthritis, and reactive arthritis show increased bone resorption, but differ with regard to bone formation. 2002 J. Rheumatol. pmid:12136902
Hofbauer LC et al. Regulation of osteoprotegerin production by androgens and anti-androgens in human osteoblastic lineage cells. 2002 Eur. J. Endocrinol. pmid:12153751
Mundy GR Metastasis to bone: causes, consequences and therapeutic opportunities. 2002 Nat. Rev. Cancer pmid:12154351
Jain RG and Lenhard JM Select HIV protease inhibitors alter bone and fat metabolism ex vivo. 2002 J. Biol. Chem. pmid:11937496
Ariyasu T et al. Trehalose augments osteoprotegerin production in the FHs74Int human intestinal epithelial cell line. 2002 In Vitro Cell. Dev. Biol. Anim. pmid:11963965
Bateman TA and Countryman S Osteoprotegerin and bone loss associated with spaceflight. 2002 Drug Discov. Today pmid:11965392
Price PA et al. Bone origin of the serum complex of calcium, phosphate, fetuin, and matrix Gla protein: biochemical evidence for the cancellous bone-remodeling compartment. 2002 J. Bone Miner. Res. pmid:12096831
Xing L et al. NF-kappaB p50 and p52 expression is not required for RANK-expressing osteoclast progenitor formation but is essential for RANK- and cytokine-mediated osteoclastogenesis. 2002 J. Bone Miner. Res. pmid:12096833
Zou W and Bar-Shavit Z Dual modulation of osteoclast differentiation by lipopolysaccharide. 2002 J. Bone Miner. Res. pmid:12096834
Koyama H et al. Melatonin at pharmacologic doses increases bone mass by suppressing resorption through down-regulation of the RANKL-mediated osteoclast formation and activation. 2002 J. Bone Miner. Res. pmid:12096835
Suda T et al. [Merger of bone biology and immunology]. 2002 Tanpakushitsu Kakusan Koso pmid:12385106
Biskobing DM et al. Novel therapeutic options for osteoporosis. 2002 Curr Opin Rheumatol pmid:12118183
Nagasawa T et al. LPS-stimulated human gingival fibroblasts inhibit the differentiation of monocytes into osteoclasts through the production of osteoprotegerin. 2002 Clin. Exp. Immunol. pmid:12390325
Mizukami J et al. Receptor activator of NF-kappaB ligand (RANKL) activates TAK1 mitogen-activated protein kinase kinase kinase through a signaling complex containing RANK, TAB2, and TRAF6. 2002 Mol. Cell. Biol. pmid:11809792
Lubberts E et al. Increase in expression of receptor activator of nuclear factor kappaB at sites of bone erosion correlates with progression of inflammation in evolving collagen-induced arthritis. 2002 Arthritis Rheum. pmid:12428250
Takahashi E et al. High extracellular calcium affects osteoclastogenesis in mouse bone marrow cell culture. 2002 J. Med. Dent. Sci. pmid:12641381
Cho CH and Nuttall ME Emerging techniques for the discovery and validation of therapeutic targets for skeletal diseases. 2002 Expert Opin. Ther. Targets pmid:12472380
Hasegawa T et al. Expression of receptor activator of NF-kappa B ligand and osteoprotegerin in culture of human periodontal ligament cells. 2002 J. Periodont. Res. pmid:12472833
Yamashita T et al. Double mutations in klotho and osteoprotegerin gene loci rescued osteopetrotic phenotype. 2002 Endocrinology pmid:12446599
Mochizuki S et al. Osteoclastogenesis inhibitory factor/osteoprotegerin ameliorates the decrease in both bone mineral density and bone strength in immobilized rats. 2002 J. Bone Miner. Metab. pmid:11810411
Childs LM et al. In vivo RANK signaling blockade using the receptor activator of NF-kappaB:Fc effectively prevents and ameliorates wear debris-induced osteolysis via osteoclast depletion without inhibiting osteogenesis. 2002 J. Bone Miner. Res. pmid:11811549
Saidenberg Kermanac'h N et al. Osteoprotegerin and inflammation. 2002 Apr-Jun Eur. Cytokine Netw. pmid:12101070
Jung K et al. Osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) in the serum of healthy adults. 2002 Jul-Sep Int. J. Biol. Markers pmid:12408468
Stilgren LS et al. Osteoprotegerin levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism. 2003 Calcif. Tissue Int. pmid:14667132
Okada T et al. Bone marrow metastatic myeloma cells promote osteoclastogenesis through RANKL on endothelial cells. 2003 Clin. Exp. Metastasis pmid:14669795
Gannagé-Yared MH et al. Effects of a short-term calcium and vitamin D treatment on serum cytokines, bone markers, insulin and lipid concentrations in healthy post-menopausal women. 2003 J. Endocrinol. Invest. pmid:14669830
Ashcroft AJ et al. Colonic dendritic cells, intestinal inflammation, and T cell-mediated bone destruction are modulated by recombinant osteoprotegerin. 2003 Immunity pmid:14670302
Min JK et al. Vascular endothelial growth factor up-regulates expression of receptor activator of NF-kappa B (RANK) in endothelial cells. Concomitant increase of angiogenic responses to RANK ligand. 2003 J. Biol. Chem. pmid:12893832
Chong B et al. Idiopathic hyperphosphatasia and TNFRSF11B mutations: relationships between phenotype and genotype. 2003 J. Bone Miner. Res. pmid:14672344
Teitelbaum SL and Ross FP Genetic regulation of osteoclast development and function. 2003 Nat. Rev. Genet. pmid:12897775
Nielsen KL et al. Biglycan deficiency interferes with ovariectomy-induced bone loss. 2003 J. Bone Miner. Res. pmid:14672350
Si AI et al. Expression and localization of extracellular matrix metalloproteinase inducer in giant cell tumor of bone. 2003 J. Cell. Biochem. pmid:12898514
Nitta K et al. The progression of vascular calcification and serum osteoprotegerin levels in patients on long-term hemodialysis. 2003 Am. J. Kidney Dis. pmid:12900812
Amizuka N et al. Defective bone remodelling in osteoprotegerin-deficient mice. 2003 J Electron Microsc (Tokyo) pmid:14756238
Fizazi K et al. Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts. 2003 Clin. Cancer Res. pmid:12855635
Kawana F and Sasaki T Osteoclast differentiation and characteristic trabecular bone formation during growth plate destruction in osteoprotegerin-deficient mice. 2003 J Electron Microsc (Tokyo) pmid:14756239
Okuma K et al. Development of a novel surrogate virus for human T-cell leukemia virus type 1: inhibition of infection by osteoprotegerin. 2003 J. Virol. pmid:12857926
Cheng X et al. The TNF receptor superfamily: role in immune inflammation and bone formation. 2003 Immunol. Res. pmid:12857975
Shin MM et al. High extracellular Ca2+ alone stimulates osteoclast formation but inhibits in the presence of other osteoclastogenic factors. 2003 Exp. Mol. Med. pmid:12858015
Glossop JR et al. No association of polymorphisms in the tumor necrosis factor receptor I and receptor II genes with disease severity in rheumatoid arthritis. 2003 J. Rheumatol. pmid:12858434
Hampson G et al. Effects of dietary improvement on bone metabolism in elderly underweight women with osteoporosis: a randomised controlled trial. 2003 Osteoporos Int pmid:12904840
Misra M et al. Serum osteoprotegerin in adolescent girls with anorexia nervosa. 2003 J. Clin. Endocrinol. Metab. pmid:12915674
Yamada T et al. Regulation of osteoclast development by Notch signaling directed to osteoclast precursors and through stromal cells. 2003 Blood pmid:12411305
Smith MD et al. Microarchitecture and protective mechanisms in synovial tissue from clinically and arthroscopically normal knee joints. 2003 Ann. Rheum. Dis. pmid:12634226
Sakurai A et al. Streptococcus pyogenes infection induces septic arthritis with increased production of the receptor activator of the NF-kappaB ligand. 2003 Infect. Immun. pmid:14500523
Kim HH et al. RANKL regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. 2003 FASEB J. pmid:14500543
Nakamura M et al. Osteoprotegerin regulates bone formation through a coupling mechanism with bone resorption. 2003 Endocrinology pmid:14500574
Zhang Z et al. Receptor activator of NF-kappa B ligand stimulates recruitment of SHP-1 to the complex containing TNFR-associated factor 6 that regulates osteoclastogenesis. 2003 J. Immunol. pmid:14500659
Ueno Y et al. In vivo administration of 1,25-dihydroxyvitamin D3 suppresses the expression of RANKL mRNA in bone of thyroparathyroidectomized rats constantly infused with PTH. 2003 J. Cell. Biochem. pmid:14505343
Kaneyama K et al. Osteoclastogenesis inhibitory factor/osteoprotegerin in synovial fluid from patients with temporomandibular disorders. 2003 Int J Oral Maxillofac Surg pmid:14505625
Grigorie D et al. Circulating osteoprotegerin and leptin levels in postmenopausal women with and without osteoporosis. 2003 Rom J Intern Med pmid:15526523
Mandelin J et al. Imbalance of RANKL/RANK/OPG system in interface tissue in loosening of total hip replacement. 2003 J Bone Joint Surg Br pmid:14653607
Malyszko J et al. Osteoprotegerin and its correlations with new markers of bone formation and bone resorption in kidney transplant recipients. 2003 Transplant. Proc. pmid:14529897
Ren W et al. Distinct gene expression of receptor activator of nuclear factor-kappaB and rank ligand in the inflammatory response to variant morphologies of UHMWPE particles. 2003 Biomaterials pmid:14530078
Wiethe C et al. Enhanced effector and memory CTL responses generated by incorporation of receptor activator of NF-kappa B (RANK)/RANK ligand costimulatory molecules into dendritic cell immunogens expressing a human tumor-specific antigen. 2003 J. Immunol. pmid:14530334
Wiethe C et al. Provision of 4-1BB ligand enhances effector and memory CTL responses generated by immunization with dendritic cells expressing a human tumor-associated antigen. 2003 J. Immunol. pmid:12626542
Wagner EF and Matsuo K Signalling in osteoclasts and the role of Fos/AP1 proteins. 2003 Ann. Rheum. Dis. pmid:14532157
Ueland T et al. Age-related changes in cortical bone content of insulin-like growth factor binding protein (IGFBP)-3, IGFBP-5, osteoprotegerin, and calcium in postmenopausal osteoporosis: a cross-sectional study. 2003 J. Clin. Endocrinol. Metab. pmid:12629078
Ueland T et al. Growth hormone substitution increases gene expression of members of the IGF family in cortical bone from women with adult onset growth hormone deficiency--relationship with bone turn-over. 2003 Bone pmid:14555269
Schoppet M et al. Increased osteoprotegerin serum levels in men with coronary artery disease. 2003 J. Clin. Endocrinol. Metab. pmid:12629080
Nagata N et al. Inhibition of RANKL-induced osteoclast formation in mouse bone marrow cells by IL-12: involvement of IFN-gamma possibly induced from non-T cell population. 2003 Bone pmid:14555278
Han W et al. Construction of a new tumour necrosis factor fusion-protein expression vector for high-level expression of heterologous genes in Escherichia coli. 2003 Biotechnol. Appl. Biochem. pmid:12630898
Koshihara Y et al. Vitamin K stimulates osteoblastogenesis and inhibits osteoclastogenesis in human bone marrow cell culture. 2003 J. Endocrinol. pmid:12630919
Grimaud E et al. Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis. 2003 Am. J. Pathol. pmid:14578201
Alvarez L et al. Serum osteoprotegerin and its ligand in Paget's disease of bone: relationship to disease activity and effect of treatment with bisphosphonates. 2003 Arthritis Rheum. pmid:12632438
Bord S et al. The effects of estrogen on osteoprotegerin, RANKL, and estrogen receptor expression in human osteoblasts. 2003 Bone pmid:12633785
Coen G et al. Serum leptin in dialysis renal osteodystrophy. 2003 Am. J. Kidney Dis. pmid:14582047
Garber K Why it hurts: researchers seek mechanisms of cancer pain. 2003 J. Natl. Cancer Inst. pmid:12783923
Chagraoui H et al. Expression of osteoprotegerin mRNA and protein in murine megakaryocytes. 2003 Exp. Hematol. pmid:14585373
Liu B et al. Multinucleated giant cells in various forms of giant cell containing lesions of the jaws express features of osteoclasts. 2003 J. Oral Pathol. Med. pmid:12787044
Eaton CL and Coleman RE Pathophysiology of bone metastases from prostate cancer and the role of bisphosphonates in treatment. 2003 Cancer Treat. Rev. pmid:12787713
Fahrleitner-Pammer A et al. Osteoprotegerin serum levels in women: correlation with age, bone mass, bone turnover and fracture status. 2003 Wien. Klin. Wochenschr. pmid:12793029
Yorke R et al. Receptor activator of nuclear factor kappaB (RANK) is expressed as a late event during malignant progression in Barrett's metaplasia. 2003 Eur. J. Cancer pmid:12957466
Kaneyama K et al. Expression of osteoprotegerin in synovial tissue and degradation of articular cartilage: comparison with arthroscopic findings of temporomandibular joint disorders. 2003 Oral Surg Oral Med Oral Pathol Oral Radiol Endod pmid:12973279
Lee ZH and Kim HH Signal transduction by receptor activator of nuclear factor kappa B in osteoclasts. 2003 Biochem. Biophys. Res. Commun. pmid:12745060
Boyle WJ et al. Osteoclast differentiation and activation. 2003 Nature pmid:12748652
Terpos E et al. Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. 2003 Blood pmid:12689925
Zheng B et al. MEK/ERK pathway is aberrantly active in Hodgkin disease: a signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival. 2003 Blood pmid:12689928
Moreno JL et al. IL-4 suppresses osteoclast development and mature osteoclast function by a STAT6-dependent mechanism: irreversible inhibition of the differentiation program activated by RANKL. 2003 Blood pmid:12689929
Dovio A et al. Autocrine down-regulation of glucocorticoid receptors by interleukin-11 in human osteoblast-like cell lines. 2003 J. Endocrinol. pmid:12697042
Nakano M et al. Inhibitory effect of titanium particles on osteoclast formation generated by treatment of mouse bone marrow cells with PGE2. 2003 Oral Dis pmid:12657033
Ra JS et al. Osteoprotegerin inhibits proliferation of myeloid progenitor cells. 2003 J. Hematother. Stem Cell Res. pmid:12662434
Szalay F et al. High serum osteoprotegerin and low RANKL in primary biliary cirrhosis. 2003 J. Hepatol. pmid:12663228
Okada Y et al. Impaired osteoclast formation in bone marrow cultures of Fgf2 null mice in response to parathyroid hormone. 2003 J. Biol. Chem. pmid:12665515
Kato I et al. TRANCE together with IL-7 induces pre-B cells to proliferate. 2003 Eur. J. Immunol. pmid:12548564
Sordillo EM and Pearse RN RANK-Fc: a therapeutic antagonist for RANK-L in myeloma. 2003 Cancer pmid:12548579
Oyajobi BO and Mundy GR Receptor activator of NF-kappaB ligand, macrophage inflammatory protein-1alpha, and the proteasome: novel therapeutic targets in myeloma. 2003 Cancer pmid:12548580
Croucher PI et al. Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease. 2003 Cancer pmid:12548581
Lipton A Bisphosphonates and metastatic breast carcinoma. 2003 Cancer pmid:12548585
Demers LM Bone markers in the management of patients with skeletal metastases. 2003 Cancer pmid:12548589
Body JJ et al. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. 2003 Cancer pmid:12548591
Liu JZ et al. [The OPG/RANKL/RANK system and bone resorptive disease]. 2003 Sheng Wu Gong Cheng Xue Bao pmid:15971575
Liu JZ et al. [Construction and biological activity study of human osteoprotegerin expressing adenoviral system]. 2003 Sheng Wu Gong Cheng Xue Bao pmid:15969033
Elhasid R et al. Familial severe congenital neutropenia associated with infantile osteoporosis: a new entity. 2003 Am. J. Hematol. pmid:12508266
Haynes DR et al. Osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathies and osteoarthritis and normal controls. 2003 Rheumatology (Oxford) pmid:12509625
Rude RK et al. Magnesium deficiency: effect on bone and mineral metabolism in the mouse. 2003 Calcif. Tissue Int. pmid:12370796

Table of Content